Tag Bevacizumab

Health

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

A new research paper was published in Oncotarget’s Volume 13 on December 6, 2022, entitled, “Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.” Hepatocellular carcinoma (HCC) has limited systemic therapy…

GT
December 23, 2022

Health

Study compares the performance of two most popular AMD drugs

A pilot, “look-back” study of information about 106 patients with “wet” age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection…

GT
December 1, 2022

Health

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM). Researchers led by Ludwig Lausanne’s Douglas Hanahan report in the current issue…

GT
September 21, 2022

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

Study compares the performance of two most popular AMD drugs

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

Trending now